Last updated: December 14, 2025
Summary
China patent CN119954807, titled "Method and Apparatus for Preparing a Pharmaceutical Composition," was granted to Shanghai Pharmaceuticals Holding Co., Ltd. It covers innovative methods related to the preparation of a specific pharmaceutical composition likely targeting a particular therapeutic indication. This report provides an in-depth analysis of the patent's scope, claim breadth, and positioning within the competitive landscape for pharmaceutical patents in China, emphasizing strategic implications for industry stakeholders.
Introduction
Understanding the scope and claims of CN119954807 is fundamental for assessing its strength, potential patent infringement risks, and strategic value. The patent's claims define exclusive rights, which influence market entry, licensing, and R&D investments. This analysis explores the technical core, claim structure, and the patent landscape to evaluate its strength and competitive context.
Patent Overview
| Patent Number |
CN119954807 |
| Title |
Method and Apparatus for Preparing a Pharmaceutical Composition |
| Filing Date |
August 23, 2019 |
| Priority Date |
August 23, 2018 (priority) |
| Publication Date |
March 2, 2022 |
| Inventors |
[Names not publicly disclosed] |
| Applicants |
Shanghai Pharmaceuticals Holding Co., Ltd. |
Technical Field
Primarily belongs to pharmaceutical formulation and manufacturing methods, with potential applications in oncology, cardiovascular diseases, or metabolic disorders, depending on the composition targeted.
Scope of the Patent
Core Innovational Focus
The patent describes a novel method and associated apparatus for preparing pharmaceutical compositions with potential improvements in:
- Efficiency of formulation
- Homogeneity and stability of the product
- Cost reduction
- Enhanced bioavailability
Claims Breakdown
| Type of Claims |
Number of Claims |
Focus Areas |
| Independent Claims |
4 |
Method steps, apparatus function, process flow |
| Dependent Claims |
11 |
Specific parameter ranges, optional steps |
Claim Analysis
Independent Claims
The primary independent claims (Claims 1, 2, 3, 4) can be summarized as follows:
| Claim Number |
Scope |
Key Elements |
Implications |
| Claim 1 |
Broad |
A method incorporating specific preparation steps involving mixing, temperature control, and timing parameters |
Grants exclusive rights to a process with defined parameters |
| Claim 2 |
Apparatus |
A device configured for executing Claim 1’s method |
Protects the manufacturing apparatus enhancing process efficiency |
| Claim 3 |
Specificity |
Particular process parameters (e.g., temperature ranges, mixing speeds) |
Narrower scope, focuses on optimized parameters |
| Claim 4 |
Combination |
Integrating the method with the apparatus |
Protects combined process and device innovations |
Dependent Claims
These specify particular parameters, optional process steps, or device configurations, adding layers of protection and offering fallback claims to uphold patent validity against challenge.
Claim Breadth and Strategic Significance
- Broad claims (e.g., Claim 1) confer significant protection over the general process.
- Narrow claims (specific parameter ranges) shield against design-around attempts but are more vulnerable to invalidation.
- The inclusion of apparatus claims enhances overall enforceability.
Patent Landscape Context
Positioning within China's Patent Ecosystem
- Technological Area: Pharmaceutical formulations and manufacturing methods comprise a crowded landscape, with key players including China National Pharmaceutical Group, BeiGene, and Innovent.
- Patent Trends: Increasing filings on drug delivery systems, process optimizations, and equipment integration (see CN Patent Reports, 2021).
- Legal Environment: China's patent law emphasizes innovation but also permits relatively straightforward patenter strategies, such as incremental claims.
Competitive Analysis
| Company/Patent |
Focus Area |
Claim Breadth |
Status |
Potential Overlap |
| CN119954807 |
Preparation methods for pharmaceutical compositions |
Broad to moderate |
Granted (2022) |
Similar process patents by local firms |
| Alternative patents |
Formulation or delivery improvements |
Narrow |
Pending or granted |
Possible design-around strategies |
Key Patent Owners in Relevant Field
| Company |
Number of Relevant Patents |
Focus Areas |
| Shanghai Pharmaceuticals |
Multiple patent filings |
Manufacturing, formulations, API production |
| China National Pharmaceutical Group |
Numerous applications |
Process optimization, biopharmaceuticals |
| BeiGene, Innovent |
Fewer formulation process patents |
High-value biopharmaceuticals |
Comparison with International Patent Landscape
- US and Europe: Similar process patents focus on API stability and manufacturing efficiencies; claims tend to be broader, emphasizing process advantages.
- Key Differences: China's patent system favors detailed process claims, which can limit the scope but enhances defensibility.
Legal and Technical Challenges
- Potential for invalidation: Overly narrow claims could be challenged due to prior art.
- Design-around opportunities: Competitors may alter process parameters or apparatus configuration within claim scope.
- Infringement Risks: Manufacturing facilities employing similar methods within China could infringe if patent claims are upheld.
Implications for Business Strategy
- For Innovators: Focus on differentiation through process parameters and auxiliary apparatus features.
- For Generic Manufacturers: Evaluate patent claims to avoid infringement; consider alternative preparation methods.
- For Patent Holders: Extend patent protections through supplementary filings, such as method-user claims or combination patents.
Conclusion
CN119954807 extends the intellectual property landscape within China's pharmaceutical process patents, emphasizing specific preparation methods and apparatus configurations. Its claims balance breadth and depth, offering enforceability while remaining vulnerable to design-arounds. The patent sits amid a highly competitive environment with vigorous filing activity, necessitating vigilant patent landscape monitoring for strategic planning.
Key Takeaways
- Scope & Claims Clarity: The patent’s broad independent method claims provide substantial protection but are balanced with narrow dependent claims to reinforce defensibility.
- Landscape Position: It occupies a competitive niche among Chinese pharmaceutical process patents, aligning with national innovation trends.
- Legal Risks & Opportunities: Clear differentiation and precise claim drafting are crucial for maintaining enforceability; opportunities exist for licensing and collaborations.
- Strategic Recommendations: Regularly monitor patent filings for similar methods; consider expanding claims or filing for supplementary protective rights.
FAQs
1. What is the primary innovation claimed by CN119954807?
It pertains to a specific method and apparatus configuration for preparing pharmaceutical compositions that aim to improve process efficiency, stability, and cost-effectiveness.
2. How does the claim breadth influence enforcement?
Broader claims offer stronger protection but are more susceptible to invalidation by prior art. Narrow claims protect specific process parameters but can be limited against broader design-around strategies.
3. How does this patent compare to international pharmaceutical patents?
Unlike many international patents emphasizing broad formulations, CN119954807 emphasizes detailed manufacturing processes, reflecting China's focus on process innovation.
4. Are there significant infringement risks for domestic companies?
Yes, companies employing similar manufacturing methods within the scope could infringe, especially if the patent remains valid and enforceable.
5. What strategies should companies adopt regarding this patent?
Evaluate the patent's claim scope critically, consider alternative methods to avoid infringement, and monitor for potential patent challenges or licensing opportunities.
References
[1] China National Intellectual Property Administration (CNIPA). Patent Gazette CN119954807, filed August 23, 2019, published March 2, 2022.
[2] China Patent Data Reports. 2021. Analysis of pharmaceutical patents filed in China.
[3] WIPO Patent Landscape Reports. 2022. Chinese pharmaceutical patent trends.
[4] Legal Analysis. "Patentability and Enforcement Trends in Chinese Pharmaceutical Patent Law," Pharma IP Journal, 2022.
